Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.65 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | HRH2 | P25021 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67079 | 0.94 | TBXA2R (0.58) | TBXA2RTBXAS1SLC6A3CACNA1FDRD4 | |
| SCHEMBL67228 | 0.86 | CACNA1B (0.53) | TBXA2RSLC6A3CACNA1FDRD4DRD5 | |
| SCHEMBL8742992 | 0.86 | TBXA2R (0.58) | TBXA2R | |
| SCHEMBL8743003 | 0.86 | TBXA2R (0.58) | TBXA2R | |
| SCHEMBL51338 | 0.83 | TBXAS1 (0.54) | TBXA2RTBXAS1LMNACYP3A4TSHR | |
| SCHEMBL8256852 | 0.83 | TBXA2R (0.52) | TBXA2RSLC6A3CACNA1FDRD4DRD5 | |
| SCHEMBL28987106 | 0.83 | TBXA2R (0.56) | TBXA2RTBXAS1LMNAFOLH1 | |
| SCHEMBL3154532 | 0.82 | TBXAS1 (0.71) | TBXA2RTBXAS1SLC6A3HTR2AADRA1A | |
| SCHEMBL7323763 | 0.81 | CACNA1B (0.49) | TBXA2RTBXAS1SLC6A3CACNA1FDRD4 | |
| SCHEMBL9092531 | 0.81 | TBXAS1 (0.56) | TBXA2RTBXAS1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | claimed |
| EP-1846365-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-10-24 | — | — | EP | claimed |
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | claimed |
| JP-2007518742-A | — | — | 2007-07-12 | — | — | JP | claimed |
| JP-2006526000-A | — | — | 2006-11-16 | — | — | JP | claimed |
| EP-1718633-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-11-08 | — | — | EP | claimed |
| US-20060235050-A1 | Diamine calcium channel blockers | NUEROMED TECHNOLOGIES, INC. (CA) | 2006-10-19 | — | — | US | claimed |
| WO-2006084369-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1633343-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Technologies, Inc. (CA) | 2006-03-15 | — | — | EP | claimed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | claimed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004105750-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-12-09 | — | — | WO | claimed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-30 | — | — | US | disclosed |
| WO-2004089922-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089922-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | disclosed |
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | TBXA2R 874/4885TBXAS1 1546/4885SLC6A3 730/4885 |
| US-20060235050-A1 | Diamine calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | TBXA2R 195/4885TBXAS1 340/4885SLC6A3 461/4885 |
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | TBXA2R 520/4885TBXAS1 745/4885SLC6A3 1160/4885 |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | TBXA2R 520/4885TBXAS1 745/4885SLC6A3 1160/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | TBXA2R 207/4885TBXAS1 416/4885SLC6A3 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.